For example, targeting the CXCR4 receptor has been explored in other cancers, with drugs like Plerixafor (AMD3100) being used to block CXCR4 [86, 87], thereby mobilizing hematopoietic stem cells and potentially influencing tumor progression. This evidence concerns the gene CXCR4 and cancer.